Olopatadine Hydrochloride

2010 ◽  
Vol 72 (2) ◽  
pp. 159-162
Author(s):  
Rieko KABASHIMA ◽  
Toshinori BITO ◽  
Makiko TAJIRI ◽  
Chika KAWAKAMI ◽  
Shoko FUKAMACHI ◽  
...  

Author(s):  
Kojiro Otsuka ◽  
Akio Niimi ◽  
Hisako Matsumoto ◽  
Isao Ito ◽  
Masafumi Yamaguchi ◽  
...  

2014 ◽  
Vol 35 (3) ◽  
pp. e104-e109 ◽  
Author(s):  
Naoya Egami ◽  
Akinobu Kakigi ◽  
Taizo Takeda ◽  
Setsuko Takeda ◽  
Rie Nishioka ◽  
...  

Author(s):  
Tahir Husain Ansari ◽  
Yusuf Rizvi

Background: Vernal keratoconjunctivitis (VKC) is a recurrent, bilateral, external, ocular inflammation primarily affecting young adults living in warm dry climates. The objectives of the research was to compare the two ophthalmic solutions of olopatadine hydrochloride (0.1%) and epinastine hydrochloride (0.05%) on clinical signs of vernal keratoconjuntivitis and to determine side effects of both the drugs.Methods: The study was carried out in 40 patients who attended the out-patient department (OPD) Ophthalmology, Darbhanga Medical College and Hospital, Laheriasarai from July 2007 to December 2008.  Forty patients with symptoms of VKC (ocular itching, ropy discharge, papillary hypertrophy, gelatinous thickening and horner-trantas spots were selected and included in our study.Results: Mean score of palpebral hyperemia at 0, 14, 28 and 42 days in olopatadine treated eye were 2.1, 1.4, 0.8 and 0.4 respectively having p value <0.01, and <0.01 and <0.05 respectively, while mean score at same stages in placebo eye were 2.1, 2, 1.9, and 1.5 having value >0.05. Epinastine treated group mean score of palpebral hyperemia were <0.01 and <0.01 respectively in epinastine treated eye whereas in placebo treated eye, mean score were 2.1, 2.0, 1.8 and 1.6 respectively having p value >0.05 in all stages. Statistically insignificant reduction at day 14 while very significant reduction at day 28 and 42 was observed in epinastine treated eye as compared to placebo.Conclusions: The present study had shown that both olopatadine and epinastine were effective in treating clinical signs of VKC as compared to placebo.


2021 ◽  
Vol 29 (1) ◽  
pp. 65
Author(s):  
Jae Hoon Kim ◽  
Minyu Lee ◽  
Namsick Kim ◽  
Tae-Young Oh ◽  
Seung-Kwan Nam ◽  
...  

2020 ◽  
Vol 2 (1) ◽  
Author(s):  
Sebaiy Mahmoud M ◽  
Abdellatef Hisham E ◽  
Elhenawee Magda M ◽  
Elmosallamy Mohamed A ◽  
Alshuwaili Mustafa Kh

Author(s):  
Jayanthi C. R. ◽  
Nanthini R. ◽  
. Vijayalakshmi

Background: Allergic conjunctivitis, an ocular surface inflammatory disease with significant social and economic impact affects approximately 25% of the general population. H1 receptor blockers, mast cell stabilizers and drugs that block cytokine and prostaglandin formation form the treatment armamentarium. Olopatadine hydrochloride and Azelastine hydrochloride are dual-acting selective H1 receptor antagonist with mast-cell stabilizing property. This study was undertaken to assess the efficacy and safety of olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% in allergic conjunctivitis amongst Indians.Methods: After obtaining Institutional Ethics Committee approval and written informed consent, 120 patients diagnosed with allergic conjunctivitis fulfilling the inclusion/exclusion criteria were enrolled in the study. Study was done from April 2014 to June 2015 at Minto eye hospital. Study subjects were treated with olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% eye drops BD for 15 days. Ocular symptoms, instead of and signs and adverse events, if any were recorded on the day 8 and day 15 follow up visits.Results: At the end of the study period, the reduction in the ocular itching score from baseline was higher in the olopatadine group compared to the azelastine group (p<0.002). Similarly, the scores of ocular congestion (p<0.008), foreign body sensation (p<0.009), tearing (p<0.001), erythema (p<0.002) and chemosis (p<0.015) also showed larger reduction in the olopatadine treated patients. The common adverse events encountered in both the groups were stinging after instillation, burning, bitter taste and headache.Conclusions: In allergic conjunctivitis, both olopatadine and azelastine were found to be effective in relieving ocular signs and symptoms, but olopatadine was found to be superior in terms of efficacy, safety and tolerability with minimal side effects.


2002 ◽  
Vol 29 (11) ◽  
pp. 709-712 ◽  
Author(s):  
Keisuke Morita ◽  
Tetsuya Koga ◽  
Yoichi Moroi ◽  
Kazunori Urabe ◽  
Masutaka Furue

Sign in / Sign up

Export Citation Format

Share Document